Evidence map›Paper›PMID 21359116›Full record

ArticleCell death & disease2011

Necrostatin-1 ameliorates symptoms in R6/2 transgenic mouse model of Huntington's disease.

S Zhu, Y Zhang, G Bai, H Li

Abstract readLetter
In one paragraph

Article in Cell death & disease, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Outcomes of RIP Kinase Signaling During Neuroinvasive Viral Infection.Current topics in microbiology and immunology · 2023
    Review
  13. Article
  14. Article
  15. Necroptosis in CNS diseases: Focus on astrocytes.Frontiers in aging neuroscience · 2022
    Review
  16. Review
  17. Non-Cell Autonomous and Epigenetic Mechanisms of Huntington's Disease.International journal of molecular sciences · 2021
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

S Zhu
Y Zhang
G Bai
H Li

Funding

Functional study of C53 protein as a novel regulator of checkpoint kinasesR01GM081776 · NIGMS · LURIE CHILDREN'S HOSPITAL OF CHICAGO · PI LI, HONGLIN · 2008 to 2012
$1.5M
REGULATION OF THE NRI GENE IN NEURONAL DIFFERENTIATIONR01NS038077 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI BAI, GUANG · 2000 to 2003
$906k
NIGMS NIH HHS R01 GM081776NIGMS NIH HHS R01GM081776NINDS NIH HHS NS38077NINDS NIH HHS R01 NS038077
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsApoptosisCell LineDisease Models, AnimalGTPase-Activating ProteinsHumansHuntington DiseaseImidazolesIndolesMiceMice, TransgenicGTPase-Activating ProteinsImidazolesIndolesnecrostatin-1Ralbp1 protein, mouse

Identifiers

PMID21359116
PMCPMC3043604

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.